Souhaitez-vous accéder aux communiqués récents ?

REYKJAVIK, Iceland, June 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech (NASDAQ: ALVO) tilkynnti í dag að Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA) hefði sent svar við annarri umsókn félagsins um markaðsleyfi fyrir AVT02, sem jafnframt inniheldur gögn sem...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...

According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and...

Samkvæmt samningnum má sala á AVT04 (ustekinumab) hefjast í Bandaríkjunum eigi síðar en 21. febrúar 2025, að fengnu samþykki lyfjayfirvalda Alvotech (NASDAQ: ALVO) og Teva Pharmaceuticals Inc.,...

According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 Alvotech (NASDAQ: ALVO), a global biotech company...

Alvotech (NASDAQ First North: ALVO) tilkynnti í dag þátttöku í heilbrigðisráðstefnu Jefferies fjárfestingabankans, sem haldin verður í New York dagana 7.-9. júni nk. Alvotech mun halda kynningu og...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

REYKJAVIK, Iceland, May 31, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and...